The publication, based on data generated from a questionnaire with 150 industry representatives, explores the challenges and solutions facing cell and gene therapy (CGT) companies over the next few years.
The top six trends identified in the CRB survey were:
We got the inside track from Noel Maestre, director of SlateXpace, a CRB solution focused on suite-based manufacturing platforms for the Advanced Therapy Medicinal Products (ATMP) and Peter Walters, CRBs director of ATMP, on how the CGT landscape is likely to develop in the short-term.
In a recent report, the MITs Center for Biomedical Innovationprojected that around 500,000 patients will have been treated with 40-60 approved gene therapies by 2030.
Going from the current scenario whereby only a few gene therapies are approved to 60 launches in a decade would represent an extraordinary leap forward and would dramatically change how medicine is actually perceived, said Maestre.
But as regards CGT production today, especially autologous cell therapy (ACT) work, he said that while the science exists the technology - process equipment, facility design and automation platforms - is really still trying to catch up, endeavoring to address a sector that has exploded in the past five years, he commented.
Looking ahead at the CGT landscape over the next few years, he expects a significant amount of change. The science is evolving we see the industry moving away from old cell lines to new cell lines or moving away from viral vectors altogether and using cleavage enzymes as a gene editing tool.
A new host cell line stable producer lines is gaining momentum, he said.
We are seeing the industry moving towards suspension cell culture from less than optimal cell lines, and then further going into producer cell lines.
A full 65% of respondents to the CRB poll said they are developing or intend to develop this type of vector host cell, drawn by the potential for a less expensive, more scalable process.
CRB: Our survey findings provide a data-driven snapshot of an industry whose intellectual capital and cutting-edge science is too often betrayed by outdated technology and applications ill-suited for commercial scale at a time when demand for urgent therapies is rising.
Once the industry gets to the point where producer cell lines are more like a name brand, easier to pull off the shelf and use, it will be a much more cost-effective way to produce viral vectors.
But we are right on the cusp - a lot of companies are recognizing the opportunity and are investing the time and money into producing these. And we also see a lot of contract development and manufacturing organizations (CDMOs) producing their own cell lines in house and using those as a lure to [attract the clinical material work] of their clients, said Walters.
According to Maestre, and the CRB survey data backs him up, the product pipelines of companies operating in the CGT space are going to get more complex, for the next five years at least.
More than half of those polled indicated they expect to adopt a multimodal solution within the next two years, with flexibility, scalability, operational efficiency, and speed to market as the top drivers.
Every company is going to be dealing with this dilemma of whether they build dedicated spaces for each of their different modalities, or whether they build highly flexible facilities that can allow them to accommodate whatever is coming next, said Maestre.
He also sees a lot more companies wanting to integrate their supply chain, bringing a lot of manufacturing in-house whereas before they would have been reliant on a whole set of different CDMOs and manufacturers.
Project delivery is also where change is occurring.
We are seeing the industry really moving away from the way projects were executed in the past into a much more integrated model; they are looking for turnkey facility delivery and they want turnaround to be faster. COVID-19 has only accentuated that, with project timelines compressed by 30-40%, and I dont think that it is ever going back to the way it was I think that is going to become the standard, commented Maestre.
And another major trend over the next few years will be around the cost of therapies. As they become more commonplace and there are more and more CGT licensed products, the costs will come down.
Projecting forward, Walters sees an eventual shift away from autologous to allogeneic cell therapy.
As the technology continues to develop and the science continues to improve and new and better ways are found to use and leverage cells, we will see companies moving to a scalable allogeneic model, getting away from having to do that point-of-care, personalized tracking and more towards a classic manufacturing model that allows them to produce cells in advance in a way that they can be scaled up.
The idea, evidently, is to process cells for not one but dozens of patients at a time.
We see the industry moving towards donated cells for allogeneic therapy and we are also seeing the beginnings of a shift to using stem cells that can be genetically modified and scaled up and differentiated to become T-Cells or NK cells. I dont think industry has settled on a course yet but there are a lot of companies trying to find that pathway, trying to find the edge to move their manufacturing platform that way, remarked Walters.
Right now, though, all facets of CGT manufacturing are under pressure from COVID-19 vaccine production, they said.
There is significant shortage of cleanroom manufacturing space to manufacture and develop the almost 1,200 CGT products in clinical trials currently.
What we are seeing is that CDMOs have so much demand - they have 12-18 months of backlog in terms of contracts for product development so they are building [new facilities] very rapidly.
As owner operator companies are stuck with that delay in getting their products into development, they are also developing a significant amount of manufacturing space on their own. But while both branches are building as fast as they can, it still isnt enough.
We are constantly hearing from our clients that they are concerned about their supply chains and being able to secure their material. Right now, a lot of companies are moving towards a combination of using CDMOs and manufacturing in-house, said Maestre.
CRB is a provider of engineering, architecture, construction and consulting solutions to the global life sciences and advanced technology industries, with over 1,300 employees.
Read the original:
Are stable producer cells the future of viral vector manufacturing and when will allogeneic cell therapy take hold? - BioPharma-Reporter.com
- Unable to find a partner for stem cell therapy, Gamida accepts sale to investment firm to survive - Fierce Biotech - March 28th, 2024
- Putting Stem Cell-Based Therapies in Context - National Institutes of ... - January 31st, 2024
- Global Stem Cell Therapy Industry Outlook to 2028, Driven by Therapeutic Innovations and Clinical Advancements ... - Yahoo Finance - January 31st, 2024
- Stem Cell Transplant and CAR T-cell Therapy: The Patient and Care Partner Experience | BMT Infonet - BMT Infonet | - January 31st, 2024
- New study on promising stem cell-based therapy for Crohn's disease - Medical Xpress - January 31st, 2024
- The Trouble With Stem Cell Therapy - Consumer Reports - December 20th, 2023
- Stem Cell Therapy Boosts Quality of Life for People With Advanced Heart Failure - MedicineNet - December 20th, 2023
- The stem cell therapy project Blue4Therapy brought to a highly successful close - Marketscreener.com - April 7th, 2023
- Stem Cell Therapy for Spinal Cord Injury - PubMed - December 27th, 2022
- How much does stem cell therapy cost in 2022? - The Niche - December 18th, 2022
- How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM - December 18th, 2022
- Ethical issues in stem cell research and therapy - December 10th, 2022
- EdiGene to Present Preliminary Safety and Efficacy Results of an Investigator Initiated Trial for ET-01, its Investigational Gene Editing... - November 6th, 2022
- Global Stem Cell Umbilical Cord Blood (UCB) Market Report 2022-2026: Increased Federal Investment in Stem Cell Therapy, and the Advent of Cord Blood... - October 21st, 2022
- Global Cell Culture Protein Surface Coating Market to Grow at a CAGR of 13.82% During 2022-2031; Market to Expand on the Back of the Technological... - October 21st, 2022
- Stem Cell Therapy for Knees - thriveMD Denver & Vail, CO - October 13th, 2022
- Stem cell therapy and autism | Raising Children Network - October 13th, 2022
- Cellectis Presents Data on Two TALEN-based Gene Therapy Preclinical Programs for Patients with ... - The Bakersfield Californian - October 13th, 2022
- Global Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027 - Yahoo Finance - October 13th, 2022
- 2023 to be highly lucrative for drug developers across therapeutic areas: Report - BSI bureau - October 13th, 2022
- Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and ... - October 4th, 2022
- Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the... - October 4th, 2022
- Innovative Imaging Techniques to Accelerate the Discovery of New... - Healthcare Tech Outlook - October 4th, 2022
- Celtic-mad dad left unable to talk after horror attack as family fundraise for stem cell therapy... - The Scottish Sun - September 25th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - Benzinga - September 16th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - GlobeNewswire - September 16th, 2022
- Radical lupus treatment uses CAR T-cell therapy developed for cancer - New Scientist - September 16th, 2022
- Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with... - September 16th, 2022
- T-Cell Redirection Therapy Shows Promise As Salvage Therapy in R/R Multiple Myeloma - Targeted Oncology - September 16th, 2022
- Orca Bio expands manufacturing capabilities to take cell therapies through to commercialization - BioPharma-Reporter.com - September 16th, 2022
- BioRestorative Therapies : BRTX Presentation September 2022 - Marketscreener.com - September 16th, 2022
- Advanced cellular therapy brings hope to KSA cancer patients - Omnia Health Insights - September 16th, 2022
- IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400 - BioSpace - September 16th, 2022
- The five hottest private biotech companies in India - Labiotech.eu - September 16th, 2022
- Be The Match and William G. Pomeroy Foundation Announce $500k Gift and Matching Campaign - PR Newswire - September 16th, 2022
- California man appears to be another person cured of HIV after a stem cell transplant - aidsmap - August 5th, 2022
- Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies - PR... - August 5th, 2022
- Induced Pluripotent Stem Cell (iPSC) Global Market to Reach $3.57 Billion by 2026 - Benzinga - August 5th, 2022
- The Role of Cell Banking Outsourcing Market Industry Growth, Competitors Analysis, New Technology, Trends and Forecast 2020 2030 - Digital Journal - August 5th, 2022
- World to Witness Surging Use of Neurostimulation & Neuromodulation Devices for Nerve Repair and Regeneration, Predicts Fact.MR - GlobeNewswire - August 5th, 2022
- Dr. Owhofasa Agbedia Honored With The 2022 ASH-CIBMTR-ASTCT Career Development Award - Business Wire - August 5th, 2022
- Novel Drug-Chemotherapy Combo After Stem Cell Transplant Associated With 'Favorable Survival Outcomes' in Group of Rare Blood Cancers - Curetoday.com - July 27th, 2022
- Broadening access to cancer fighting therapy led by UH researcher | University of Hawaii System News - University of Hawaii - July 27th, 2022
- Petition calling for 'life-changing' MS treatment funding handed to Parliament - Stuff - July 27th, 2022
- How effective is stem cell therapy for liver cirrhosis? - Times of India - July 27th, 2022
- Kite's CAR T-cell Therapy Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) - Gilead Sciences - July 27th, 2022
- S'porean doctor, a sought-after top expert in cell therapy, appointed to WHO expert panel - The Straits Times - July 27th, 2022
- Top 10 Advances in Large B-Cell Lymphomas in the Past 10 Years - Targeted Oncology - July 27th, 2022
- Stem Cell Therapy Market Emerging Trends to Make Driving Growth on Key Players Status - Taiwan News - July 19th, 2022
- PROMISING STEM CELL THERAPY IN THE MANAGEMENT OF HIV & AIDS | BTT - Dove Medical Press - July 11th, 2022
- Global Stem Cell Manufacturing Market Value Projected To Reach USD 21.71 Billion By 2029, Registering A CAGR Of 9.1% - Digital Journal - July 11th, 2022
- Diabetic foot treatment: Here's all you need to know about stem cell therapy - Hindustan Times - July 11th, 2022
- Every 5 minutes someone in India is diagnosed with blood cancer or a blood disorder: Patrick Paul, CEO, DKMS BMST Foundation India - The Financial... - July 11th, 2022
- Growing Prevalence & Recurrence Of Rheumatoid Arthritis Is Expected To Growth Of The Rheumatoid Arthritis Stem Cell Therapy Market Designer Women... - July 11th, 2022
- New sickle cell disease gene therapies depend on getting the right mouse - EurekAlert - July 11th, 2022
- Market Share, Supply, Analysis and Forecast of Human Insulin Drugs and Delivery Devices to 2026 Designer Women - Designer Women - July 3rd, 2022
- Gamida Cell Submits Biologics License Application for Omidubicel to the FDA - Pharmacy Times - June 22nd, 2022
- Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -... - June 22nd, 2022
- Stem Cell Therapy in Jacksonville at Pangenics Regenerative Center - June 13th, 2022
- Stem-Cell Based Therapy Shows Promise in Treating High-Risk Type 1 Diabetes - Newswise - June 13th, 2022
- What Is Myelofibrosis? Symptoms, Causes, Diagnosis, Treatment, and Prevention - Everyday Health - June 13th, 2022
- European Commission Approves Mosunetuzumab for Patients with R/R Follicular Lymphoma - Targeted Oncology - June 13th, 2022
- Global Human Embryonic Stem Cell Market To Be Driven By The Rapid Technological Advancements In The Forecast Period Of 2022-2027 The Greater... - June 4th, 2022
- Pancreatic Cancer Therapy Experiment Saves Woman; Is It A Breakthrough? - Kaiser Health News - June 4th, 2022
- Dedication, Achievement and Grace in Cancer Care - Curetoday.com - June 4th, 2022
- Nerve Repair and Regeneration Market worth $11.6 billion by 2027 - Exclusive Report by MarketsandMarkets - Yahoo Finance - June 4th, 2022
- Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis - DocWire News - June 4th, 2022
- CPX-351 in Treatment of AML and Clinical Considerations - OncLive - June 4th, 2022
- High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study - AJMC.com Managed Markets Network - June 4th, 2022
- JASPER THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - May 15th, 2022
- Cell Culture Market to Gain US$ 27.6 Bn by 2031, Burgeoning Demand for Biosimilars and Biologic Therapeutics Fueling Market Growth - BioSpace - May 15th, 2022
- Pilot Study Shows Promising Results With CPX-351 in Relapsed/Refractory ALL - OncLive - May 15th, 2022
- Primary Cell Culture Market Mechanical Separation Segment Is Expected To Witness A Lucrative CAGR Of 11.7 - Benzinga - May 15th, 2022
- Vale man with MS needs 50,000 for treatment in Mexico - Evesham Journal - May 2nd, 2022
- Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO... - May 2nd, 2022
- Long-Term Axi-Cel Data 'May Be Suggestive of a Cure' in Patients With Large B-Cell Lymphoma - Curetoday.com - May 2nd, 2022
- Billy Connolly donates painting to Glasgow woman diagnosed with cancer five times - Glasgow Times - May 2nd, 2022
- The Progress Made in Stem Cell Therapy, Regenerative Medicine: Peter J. McAllister, MD, FAAN - Neurology Live - April 19th, 2022
- AACR: Resistance Mechanisms to CAR-T Cell Therapy ID'd in ALL - HealthDay News - April 19th, 2022
- 2022-04-18 | NDAQ:BRTX | Press Release | BioRestorative Therapies Inc - Stockhouse - April 19th, 2022